Forma Therapeutics Holdings, Inc. announced that the first patient has been dosed in a Phase I clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer.
[Forma Therapeutics Holdings, Inc.]
0